首页> 外文期刊>World Journal of Gastroenterology >Levels of plasma des-γ-carboxy protein C and prothrombin in patients with liver diseases
【24h】

Levels of plasma des-γ-carboxy protein C and prothrombin in patients with liver diseases

机译:肝病患者血浆des-γ-羧基蛋白C和凝血酶原的水平

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To study the plasma des-γ-carboxy protein C activity, antigen and prothrombin levels in patients with liver diseases and their clinical significance. METHODS: Plasma protein C activity (PC:C) was detected by chromogenic assay and antigen (PC:Ag) and des-γ-carboxy protein C (DCPC) were detected by ELISA. Total prothrombin and unabsorbed prothrombin in plasma were detected by ecarin chromogenic assay. RESULTS: Compared with the control, the levels of PC:C and PC:Ag in patients with hepatocellular carcinoma (HCC) and liver cirrhosis (LC) were lower (PC:C: 104.65 +- 23.0%, 62.50 +- 24.89%, 56.75 +- 20.14%, PC:Ag: 5.31 +- 1.63 μg/mL, 2.28 +- 1.15 μg/mL, 2.43 +- 0.79 μg/mL, P < 0.05). The levels of PC:Ag in patients with acute viral hepatitis (AVH) also was lower (2.98 +- 0.91 μg/mL, P < 0.01), but PC:C was close to the control (93.76 +- 30.49%, P > 0.05). The levels of DCPC in patients with HCC were remarkably higher (0.69 +- 0.29 μg/mL, 1.18 +- 0.63 μg/mL, 0.45 +- 0.21 μg/mL, P > 0.05) and its average was up to 50% of total PC:Ag. But those of DCPC in patients with AVH were not significantly different from the control. The levels of total prothrombin were lower in patients with LC, but higher in patients with HCC. The levels of unabsorbed prothrombin were predominantly higher than those of other groups. CONCLUSION: PC:C and PC:Ag in patients with liver diseases (except PC:C in AVH) were lower. The total prothrombin was lower in patients with LC. The higher level of unabsorbed prothrombin may be used as a scanning marker for HCC. DCPC may be used as a complementary marker in the diagnosis of HCC.
机译:目的:研究肝病患者血浆des-γ-羧基蛋白C的活性,抗原和凝血酶原水平及其临床意义。方法:采用显色法检测血浆蛋白C活性(PC:C),用ELISA法检测抗原(PC:Ag)和去γ-羧基蛋白C(DCPC)。通过依卡琳显色法检测血浆中的总凝血酶原和未吸收的凝血酶原。结果:与对照组相比,肝细胞癌(HCC)和肝硬化(LC)患者的PC:C和PC:Ag水平较低(PC:C:104.65 +-23.0%,62.50 +-24.89%, 56.75±20.14%,PC:Ag:5.31±1.63μg/ mL,2.28±1.15μg/ mL,2.43±0.79μg/ mL,P <0.05)。急性病毒性肝炎(AVH)患者的PC:Ag水平也较低(2.98 +-0.91μg/ mL,P <0.01),但PC:C接近于对照组(93.76 +-30.49%,P> 0.05)。肝癌患者的DCPC水平显着升高(0.69 +-0.29μg/ mL,1.18 +-0.63μg/ mL,0.45 +-0.21μg/ mL,P> 0.05),其平均值最高占总数的50% PC:银。但AVH患者的DCPC与对照组无显着差异。 LC患者总凝血酶原水平较低,而HCC患者较高。未吸收的凝血酶原水平主要高于其他组。结论:肝病患者的PC:C和PC:Ag(AVH中PC:C除外)较低。 LC患者的总凝血酶原含量较低。较高水平的未吸收凝血酶原可用作HCC的扫描标记。 DCPC可用作HCC诊断的补充标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号